This website is for UK Healthcare Professionals only

This promotional material is intended for UK Healthcare Professionals (HCPs) experienced in the diagnosis and management of Parkinson’s disease only. Adverse event reporting can be found below

DUODOPA (levodopa/carbidopa intestinal gel) is indicated for the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.1

Levodopa may activate malignant melanoma, so DUODOPA should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma.1

Some patients may not be suitable for DUODOPA. You are strongly advised to read the Prescribing Information (PI) and Summary of Product Characteristics (SmPC), accessible via the links above, to evaluate patient suitability.

Frequently Asked Questions

General

How is DUODOPA prescribed?

DUODOPA is prescribed at specialist centres around the United Kingdom. Patients are referred into specialist centres, where they are then assessed for the appropriate non-oral therapy. Should DUODOPA be selected, their treatment will then be initiated here.2

Can DUODOPA treatment be stopped?

Yes. Treatment with DUODOPA using a permanent tube can be discontinued at any time by withdrawing the tube and letting the wound heal.1

Should the tubing be cleaned regularly?

It’s important to keep the system clean and to flush out the ports and tubing. Both the PEG Tube (via the white or blue "g" port) and J Tube (via the green "i" port) should each be flushed through once daily with at least 20 ml of room temperature tap or drinking water. More details for cleaning can be found in your Patient Pocket Guide.3

Pump Guidance & Operation

How is the dose adjusted?

The dose will be programmed, and can only be modified, by the doctor in charge. Before changing the programmed dose, the pump should be set to lock level 0 (LL0). Full instructions on dose adjustment are given in the Operator's manual.4

Is 24-hour therapy possible with DUODOPA?

Treatment is usually administered during the patients awake period. If medically justified, DUODOPA may be administered for up to 24 hours.1

Can the DUODOPA cassette be used the next day?

No, the cassettes can only be used for up to 24 hours once out of the refrigerator. The cartridges must be disposed of after use, even if they still contain residual gel. Do not reuse an opened cassette.1

How many cassettes will be prescribed?

This depends on the individual’s dosing needs. However, the maximum recommended daily dose is 200 ml of DUODOPA (containing 4 g levodopa and 1 g carbidopa and is equivalent to two cassettes per day).1

Can the patient take a shower or bath with the CADD-Legacy 1400 pump, used to administer DUODOPA? 

No, since the pump is only splash-proof, it must be removed before showering or bathing.5

What is the battery life with DUODOPA?

The life of the batteries is dependent on the amount of DUODOPA delivered, delivery rate, battery age, and the temperature. At the rate of 100 ml per day (one cassette), alkaline batteries will usually last about 7 days.4

Everyday Life, Travelling & Carrier Systems

What needs to be considered with regards to nutrition?

For some patients, DUODOPA may not work well if it is taken with, or shortly after eating, protein-rich food – such as meats, fish, dairy products, seeds, and nuts.6

How should DUODOPA be stored?

DUODOPA must be refrigerated (2-8 °C) and the cassette should be kept in the outer carton in order to protect from light.1

What do patients need to consider when travelling while on DUODOPA therapy?

Travel is possible. Patients must have treatment documentation and a cooler bag.1

Is air travel permitted with DUODOPA?

Patients may need to check with the airport authorities to ensure that they follow the airport regulations for carrying the pump through security.

Contact us

Please complete the form below and a member of the DUODOPA team will get back to you.

Please fill in your details below only if you are a UK registered healthcare professional and would like to contact an AbbVie representative.

Please enter First name
Please enter Last name
Please enter Role
E-mail address is not valid
Please enter Last name
Please enter Hospital name
Please enter Hospital postcode
Request a meeting with your local AbbVie representative
Please select one field.


Please refer to the AbbVie privacy notice here for more information on how AbbVie processes your personal data and your data privacy rights.

*Denotes mandatory field

Incorrect. Please try again.

References

  1. DUODOPA (levodopa/carbidopa intestinal gel) Summary of Product Characteristics.
  2. LCIG Clinical Commissioning Policy. Available at: https://www.engage.england.nhs.uk/consultation/specialised-services-consultation/user_uploads/duodopa-policy.pdf. Accessed December 2023.
  3. AbbVie J: INTESTINAL TUBE 9 FR for PEG 15 FR. Information for use.
  4. Legacy DUODOPA Operator's Manual. CADD Legacy DUODOPA Pump Model 1400.
  5. Legacy DUODOPA Patient Information. CADD Legacy DUODOPA Pump Model 1400.
  6. DUODOPA patient information leaflet. (2020). Available at: https://www.medicines.org.uk/emc/product/6231/pil. Accessed December 2023.

References

  1. DUODOPA (levodopa/carbidopa intestinal gel) Summary of Product Characteristics.
  2. LCIG Clinical Commissioning Policy. Available at: https://www.engage.england.nhs.uk. Accessed December 2023.
  3. AbbVie J: INTESTINAL TUBE 9 FR for PEG 15 FR. Information for use.
  4. Legacy DUODOPA Operator's Manual. CADD Legacy DUODOPA Pump Model 1400.
  5. Legacy DUODOPA Patient Information. CADD Legacy DUODOPA Pump Model 1400.
  6. DUODOPA patient information leaflet. (2020). Available at: https://www.medicines.org.uk. Accessed December 2023.

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores.

Adverse events should also be reported to AbbVie on GBPV@abbvie.com

 

UK-DUOD-230108. Date of preparation: December 2023.